CF PharmTech, Inc. (HKG:2652)

Hong Kong · Delayed Price · Currency is HKD

11.00

+0.37 (3.48%)

Sep 18, 2026, 4:08 PM HKT

Market Cap	4.47B
Revenue (ttm)	504.27M -27.7%
Net Income	-7.84M
EPS	-0.02
Shares Out	406.36M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,071,400
Open	10.63
Previous Close	10.63
Day's Range	10.63 - 11.30
52-Week Range	8.88 - 48.80
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 31, 2026

About CF PharmTech

CF PharmTech, Inc. engages in research and development, production, and sale of respiratory drugs and other related medical products in China. It offers Shufeimin, an azelastine hydrochloride and fluticasone propionate nasal spray; ChangQi, a budesonide inhalation suspension solution; ChangShu, a salbutamol sulfate inhalation solution; and piezoelectric mesh nebulizer, electric nasal cleaner, BFS hypertonic and physiological seawater nasal cleansing fluid products under the ChangShu name. The company also develops products for the treatment of ... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2007

Employees 625

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2652

Full Company Profile

Financial Performance

In 2025, CF PharmTech's revenue was 432.52 million, a decrease of -28.83% compared to the previous year's 607.75 million. Earnings were 2.49 million, a decrease of -88.22%.

Financial numbers in CNY Financial Statements